BioNTech: From Pandemic Profits to a Fierce Fight Against Cancer
BioNTech is pivoting from its COVID-19 vaccine success to focus on innovative cancer therapies using mRNA technology. Despite a decline in revenue and a net loss of around 700 million…
BioNTech is pivoting from its COVID-19 vaccine success to focus on innovative cancer therapies using mRNA technology. Despite a decline in revenue and a net loss of around 700 million…